The role of apoptosis in growth and survival of endometriotic cells : its implication for treatment of endometrisois
| Project/Area Number |
20591915
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
HARADA Tasuku Tottori University, 医学部, 教授 (40218649)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TERAKAWA Naoki 鳥取大学, 名誉教授 (90163906)
TANIGUCHI Fuminori 鳥取大学, 医学部・附属病院, 講師 (40322218)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 子宮内膜症 / アポトーシス / survivin / サイトカイン |
|---|
| Research Abstract |
Decreased susceptibility of endometrial tissue to apoptosis may contribute to the pathogenesis of endometriosis. Endometriotic stromal cells showed resistance to drug-induced apoptosis compared with eutopic endometrial cells. Survivin gene and protein expression was enhanced in endometriotic cells and tissues. Survivin may play a critical role in susceptibility of endometriosis to apoptosis. The data also suggest that survivin inhibitor may be effective as a therapeutic agent for endometriosis.
|
Report
(4 results)
Research Products
(39 results)
-
-
-
-
-
-
-
-
-
-
[Journal Article] TAK1 activation for cytokine synthesis and proliferation of endometriotic cells.2009
Author(s)
Taniguchi F, Harada T, Miyakoda H, Iwabe T, Deura I, Tagashira Y, Miyamoto A, Watanabe A, Suou K, Uegaki T, Terakawa N
-
Journal Title
MolCell Endocrinol. 307(1-2)
Pages: 196-204
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
